Eli Lilly lifts full-year forecast
Photo: Darron Cummings/AP/TT

Eli Lilly lifts full-year forecast after revenue jumps 48% in second quarter

American Eli Lilly, a rival to Danish weight-loss giant Novo Nordisk, increased revenue by 48 percent in the second quarter, beating expectations by a wide margin. The stock rose 6 percent in pre-market trading on the New York Stock Exchange.

Advertisement

Sales totaled $23 billion, compared with analysts' expectations of $20.6 billion, according to a Bloomberg compilation of forecasts.

The company is raising its full-year forecast. Eli Lilly now forecasts revenue of $85-87 billion for the full year, compared with a previous forecast of $82-85 billion.

Adjusted earnings per share increased 33 percent year over year to $8.38 in the quarter, higher than the expected $6.31.

Eli Lilly, with the best-selling Zepbound and Mounjaro, is often described as Novo Nordisk's arch-rival in weight-loss drugs. Novo Nordisk fell 5 percent on the Copenhagen Stock Exchange after its report.

AuthorTT News AgencyEnglish edition by Sweden Herald, adapted for our readers
Was this useful?

What do you think?

Keep readingmore from Business

All